Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of ...

IT can’t sit back - the company’s 2,000 technology professionals must drive the identification of digital solutions to ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

Boehringer Ingelheim licenses Cue Biopharma's CUE-501 bispecific antibody for $12M upfront, $345M in milestones to target ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

Cue Biopharma (CUE) stock in focus as the company collaborates with Boehringer Ingelheim to develop CUE-501, for autoimmune ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ($31.06 million) to a new R&D facility specifically focused on the modality.

Boehringer Ingelheim strengthens footprint in Swiss biotech innovation hub. Today NBE Therapeutics (NBE) a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility ...

driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer. Boehringer Ingelheim strengthens footprint in Swiss biotech innovation ...